Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider.

Geer EB, Sisco J, Adelman DT, Ludlam WH, Haviv A, Gelbaum D, Liu S, Mathias SD, Shi L.

Pituitary. 2019 Dec 5. doi: 10.1007/s11102-019-01013-2. [Epub ahead of print]

PMID:
31808101
2.

Development of a novel patient-reported measure for acromegaly: the Acro-TSQ.

Fleseriu M, Fogelfeld L, Gordon MB, Sisco J, Colwell HH, Ludlam WH, Haviv A, Mathias SD.

Pituitary. 2019 Dec;22(6):581-593. doi: 10.1007/s11102-019-00986-4.

3.

Patients with Acromegaly Presenting with Colon Cancer: A Case Series.

Gordon MB, Nakhle S, Ludlam WH.

Case Rep Endocrinol. 2016;2016:5156295. doi: 10.1155/2016/5156295. Epub 2016 Nov 29.

4.

Diagnosis of Cushing's disease in a patient with consistently normal urinary free cortisol levels: a case report.

Moloney KJ, Mercado JU, Ludlam WH, Broyles FE.

Clin Case Rep. 2016 Nov 9;4(12):1181-1183. eCollection 2016 Dec.

5.

INCIDENCE AND PREVALENCE OF ACROMEGALY IN THE UNITED STATES: A CLAIMS-BASED ANALYSIS.

Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH.

Endocr Pract. 2016 Nov;22(11):1327-1335. Epub 2016 Aug 19.

PMID:
27540880
6.

Incidence and prevalence of acromegaly in a large US health plan database.

Burton T, Le Nestour E, Neary M, Ludlam WH.

Pituitary. 2016 Jun;19(3):262-7. doi: 10.1007/s11102-015-0701-2.

7.

IDENTIFICATION OF POTENTIAL MARKERS FOR CUSHING DISEASE.

Broder MS, Chang E, Cherepanov D, Neary MP, Ludlam WH.

Endocr Pract. 2016 May;22(5):567-74. doi: 10.4158/EP15914.OR. Epub 2016 Jan 20.

PMID:
26789346
8.

Algorithm development and the clinical and economic burden of Cushing's disease in a large US health plan database.

Burton T, Le Nestour E, Neary M, Ludlam WH.

Pituitary. 2016 Apr;19(2):167-74. doi: 10.1007/s11102-015-0695-9.

9.

Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.

Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

J Med Econ. 2016;19(4):374-85. doi: 10.3111/13696998.2015.1127816. Epub 2016 Jan 12.

PMID:
26629745
10.

Patterns of pharmacologic treatment in US patients with acromegaly.

Broder MS, Chang E, Ludlam WH, Neary MP, Carmichael JD.

Curr Med Res Opin. 2016 May;32(5):799-805. doi: 10.1185/03007995.2015.1125870. Epub 2016 Jan 5.

PMID:
26609770
11.

HISTORICAL RESPONSE RATES OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF ACROMEGALY: A SYSTEMATIC REVIEW.

Shanik MH, Cao PD, Ludlam WH.

Endocr Pract. 2016 Mar;22(3):350-6. doi: 10.4158/EP15913.RA. Epub 2015 Oct 5. Review.

PMID:
26437217
12.

Incremental healthcare resource utilization and costs in US patients with Cushing's disease compared with diabetes mellitus and population controls.

Broder MS, Neary MP, Chang E, Ludlam WH.

Pituitary. 2015 Dec;18(6):796-802. doi: 10.1007/s11102-015-0654-5.

PMID:
25841733
13.

Treatment patterns in Cushing's disease patients in two large United States nationwide databases: application of a novel, graphical methodology.

Broder MS, Neary MP, Chang E, Cherepanov D, Sun GH, Ludlam WH.

Pituitary. 2015 Aug;18(4):474-9. doi: 10.1007/s11102-014-0598-1.

PMID:
25246076
14.

Burden of illness, annual healthcare utilization, and costs associated with commercially insured patients with Cushing disease in the United States.

Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH.

Endocr Pract. 2015 Jan;21(1):77-86. doi: 10.4158/EP14126.OR.

PMID:
25148813
15.

Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.

Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH.

Pituitary. 2015 Jun;18(3):283-9. doi: 10.1007/s11102-014-0569-6.

PMID:
24803324
16.

Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.

Truong HL, Nellesen D, Ludlam WH, Neary MP.

J Med Econ. 2014 Apr;17(4):288-95. doi: 10.3111/13696998.2013.877470. Epub 2014 Mar 11.

PMID:
24617917
17.

Detecting post-surgical recurrence in a patient with Cushing's disease.

Moloney KJ, Mercado JU, Ludlam WH, Mayberg MR.

J Neurooncol. 2014 Mar;117(1):191-3. doi: 10.1007/s11060-013-1343-8. Epub 2014 Feb 12. No abstract available.

18.

Delayed postoperative hyponatremia after transsphenoidal surgery: prevalence and associated factors.

Hussain NS, Piper M, Ludlam WG, Ludlam WH, Fuller CJ, Mayberg MR.

J Neurosurg. 2013 Dec;119(6):1453-60. doi: 10.3171/2013.8.JNS13411. Epub 2013 Sep 20.

PMID:
24053496
19.

Pasireotide (SOM230): a novel pituitary-targeted medical therapy for the treatment of patients with Cushing's disease.

Moloney KJ, Mercado JU, Ludlam WH, Mayberg MR.

Expert Rev Endocrinol Metab. 2012 Sep;7(5):491-502. doi: 10.1586/eem.12.49.

PMID:
30780888
20.

Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.

Ludlam WH, Anthony L.

Adv Ther. 2011 Oct;28(10):825-41. doi: 10.1007/s12325-011-0062-9. Epub 2011 Sep 28. Review.

PMID:
21964965
21.

Cushing's syndrome might be underappreciated in patients seeking bariatric surgery: a plea for screening.

Fleseriu M, Ludlam WH, Teh SH, Yedinak CG, Deveney C, Sheppard BC.

Surg Obes Relat Dis. 2009 Jan-Feb;5(1):116-9. doi: 10.1016/j.soard.2008.09.011. Epub 2008 Sep 26. No abstract available.

PMID:
18996772
22.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J.

J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28.

PMID:
18957506
23.

Cyclic Cushing syndrome: definitions and treatment implications.

Velez DA, Mayberg MR, Ludlam WH.

Neurosurg Focus. 2007;23(3):E4; discussion E4a. Review.

PMID:
17961029
24.

Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful.

Fleseriu M, Loriaux DL, Ludlam WH.

Curr Opin Endocrinol Diabetes Obes. 2007 Aug;14(4):323-8. Review.

PMID:
17940460
25.

Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience.

Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC.

Ann Surg. 2007 May;245(5):790-4.

26.

The acetyltransferase activity of CBP is required for wingless activation and H4 acetylation in Drosophila melanogaster.

Ludlam WH, Taylor MH, Tanner KG, Denu JM, Goodman RH, Smolik SM.

Mol Cell Biol. 2002 Jun;22(11):3832-41.

27.

The adult growth hormone deficiency syndrome.

Cook DM, Ludlam WH, Cook MB.

Adv Intern Med. 2000;45:297-315. Review.

PMID:
10635053
28.

Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults.

Cook DM, Ludlam WH, Cook MB.

J Clin Endocrinol Metab. 1999 Nov;84(11):3956-60.

PMID:
10566634
29.
30.

mRNAs encoding muscarinic and substance P receptors in cultured sympathetic neurons are differentially regulated by LIF or CNTF.

Ludlam WH, Zang Z, McCarson KE, Krause JE, Spray DC, Kessler JA.

Dev Biol. 1994 Aug;164(2):528-39.

PMID:
7519157
31.

Cytokine-induced programmed death of cultured sympathetic neurons.

Kessler JA, Ludlam WH, Freidin MM, Hall DH, Michaelson MD, Spray DC, Dougherty M, Batter DK.

Neuron. 1993 Dec;11(6):1123-32.

PMID:
8274279

Supplemental Content

Loading ...
Support Center